Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death

Blood

Volumn 123, Issue 19, 2014, Pages 2997-3006

  Yin, Li ^a   Kufe, Turner ^b   Avigan, David ^b   Kufe, Donald ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 8; GLUCOSE 6 PHOSPHATE; GLUTATHIONE; GO 203; MUCIN 1; MUCIN 1 C TERMINAL SUBUNIT; P53 INDUCIBLE REGULATOR OF GLYCOLYSIS AND APOPTOSIS; PROTEIN; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; (ARGININE)9-CYSTEINYL-GLUTAMINYL-CYSTEINYL-ARGINYL-ARGINYL-LYSYL-ASPARAGINE; BORONIC ACID DERIVATIVE; C12ORF5 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; PEPTIDE; PROTEIN SUBUNIT; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GLYCOLYSIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PROTEIN SUBUNIT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLUTATHIONE; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCIN-1; MULTIPLE MYELOMA; PEPTIDES; PROTEIN SUBUNITS; PYRAZINES; REACTIVE OXYGEN SPECIES;

EID: 84900441753     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-539395     Document Type: Article

References (51)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans. 2007;35(pt 1):12-17.
3. Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40(5):634-651.
4. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-4916. (Pubitemid 43882644)
5. Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma. 2009;50(6):974-984.
6. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739-789. (Pubitemid 40995523)
7. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141(4):494-503. (Pubitemid 351550556)
8. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184-190.
9. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076. (Pubitemid 32691956)
10. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639-16647. (Pubitemid 34967682)
11. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489-2499.
12. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib. Leuk Res. 2006;30(2):240-241. (Pubitemid 41773346)
13. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107(10):4053-4062. (Pubitemid 43726814)
14. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138(6):783-791. (Pubitemid 47313207)
15. McMillin DW, Ooi M, Delmore J, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009;69(14):5835-5842.
16. Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120(16):3260-3270.
17. Takahashi T, Makiguchi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol. 1994;153(5):2102-2109. (Pubitemid 24256681)
18. Burton J, Mishina D, Cardillo T, et al. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res. 1999;5(10,suppl):3065s-3072s. (Pubitemid 29493897)
19. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999;93(4):1287-1298. (Pubitemid 29076144)
20. Cloosen S, Gratama J, van Leeuwen EB, et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol. 2006;135(4):513-516. (Pubitemid 44583416)
21. Baldus SE, Palmen C, Thiele J. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol. 2007;22(8):889-893. (Pubitemid 47034155)
22. Kawano T, Ahmad R, Nogi H, Agata N, Anderson K, Kufe D. MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 2008;33(1):153-159.
23. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874-885.
24. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009;8(13):1197-1203.
25. Leng Y, Cao C, Ren J, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007;282(27):19321-19330. (Pubitemid 47100108)
26. Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009;69(12):5133-5141.
27. Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10(5):806-816.
28. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteinemediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012;40(5):1643-1649.
29. Yin L, Ahmad R, Kosugi M, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010;78(2):166-174.
30. Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012;119(3):810-816.
31. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290. (Pubitemid 350106321)
32. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009; 113(19):4667-4676.
33. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia. 2003;17(10):2036-2045. (Pubitemid 37322135)
34. Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal. 2009;11(5):1123-1137.
35. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107-120. (Pubitemid 44040989)
36. Gutiérrez-Uzquiza A, Arechederra M, Bragado P, Aguirre-Ghiso JA, Porras A. p38a mediates cell survival in response to oxidative stress via induction of antioxidant genes: effect on the p70S6K pathway. J Biol Chem. 2012;287(4):2632-2642.
37. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10(11):3839-3852. (Pubitemid 38697620)
38. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced antimultiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 2007;139(3):385-397. (Pubitemid 47512171)
39. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11(3):619-633. (Pubitemid 36385118)
40. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9(12):2277-2293. (Pubitemid 350059010)
41. Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci U S A. 2008; 105(47):18525-18530.
42. Cheung EC, Athineos D, Lee P, et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell. 2013;25(5):463-477.
43. Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle. 2008;7(15):2341-2345.
44. Marciniak SJ, Yun CY, Oyadomari S, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18(24):3066-3077. (Pubitemid 39658175)
45. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008;118(10):3378-3389.
46. Puthalakath H, O'Reilly LA, Gunn P, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129(7):1337-1349. (Pubitemid 46962086)
47. Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms macroglobulinemia. Leuk Lymphoma. 2009;50(5):694-702.
48. Chen C, Xu Y, Song Y. IGF-1 gene-modified muscle-derived stem cells are resistant to oxidative stress via enhanced activation of IGF-1R/PI3K/AKT signaling and secretion of VEGF. Mol Cell Biochem. 2014;386(1-2):167-175.
49. Du ZX, Zhang HY, Meng X, Guan Y, Wang HQ. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer. 2009;9:56.
50. Kim SJ, Jung HJ, Lim CJ. Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress. Biochem Genet. 2013;51(11-12):901-915.
51. Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci U S A. 2012;109(50):20491-20496.